GT160-246, a Toxin Binding Polymer for Treatment of Clostridium difficile Colitis
- 1 August 2001
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (8) , 2340-2347
- https://doi.org/10.1128/aac.45.8.2340-2347.2001
Abstract
GT160-246, a high-molecular-weight soluble anionic polymer, was tested in vitro and in vivo for neutralization of Clostridium difficile toxin A and B activities. Five milligrams of GT160-246 per ml neutralized toxin-mediated inhibition of protein synthesis in Vero cells induced by 5 ng of toxin A per ml or 1.25 ng of toxin B per ml. In ligated rat ileal loops, 1 mg of GT160-246 neutralized fluid accumulation caused by 5 μg of toxin A. At doses as high as 80 mg/loop, cholestyramine provided incomplete neutralization of fluid accumulation caused by 5 μg of toxin A. GT160-246 protected 80% of the hamsters from mortality caused by infection with C. difficile, whereas cholestyramine protected only 10% of animals. Treatment of C. difficile-infected hamsters with metronidazole initially protected 100% of the hamsters from mortality, but upon removal of treatment, 80% of the hamsters had relapses and died. In contrast, removal of GT160-246 treatment did not result in disease relapse in the hamsters. GT160-246 showed no antimicrobial activity in tests with a panel of 16 aerobic bacteria and yeast and 22 anaerobic bacteria and did not interfere with the in vitro activities of most antibiotics. GT160-246 offers a novel, nonantimicrobial treatment of C. difficile disease in humans.Keywords
This publication has 35 references indexed in Scilit:
- Antibiotics and Clostridium difficile diarrhea in the ambulatory care settingClinical Therapeutics, 2000
- Pseudomembranous Colitis: Causes and CuresDigestion, 1999
- Recurrent Clostridium Difficile Disease: Epidemiology and Clinical CharacteristicsInfection Control & Hospital Epidemiology, 1999
- Clostridium difficile InfectionAnnual Review of Medicine, 1998
- Financial burden of hospital-acquired Clostridium difficile infectionJournal of Hospital Infection, 1996
- A receptor decoy inhibits the enterotoxic effects of Clostridium difficile toxin A in rat ileumGastroenterology, 1996
- Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro.Journal of Clinical Investigation, 1995
- Oligosaccharide Sequences Attached to an Inert Support (SYNSORB) as Potential Therapy for Antibiotic-Associated Diarrhea and Pseudomembranous ColitisThe Journal of Infectious Diseases, 1994
- Binding of Clostridium difficile Cytotoxin and Vancomycin by Anion-Exchange ResinsThe Journal of Infectious Diseases, 1980
- Pseudomembranous colitis. Association with antibiotics and therapy with cholestyraminePublished by American Medical Association (AMA) ,1975